Zoetis Inc. $ZTS Shares Purchased by Chemistry Wealth Management LLC

Chemistry Wealth Management LLC boosted its stake in Zoetis Inc. (NYSE:ZTS) by 504.4% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 19,696 shares of the company’s stock after buying an additional 16,437 shares during the period. Chemistry Wealth Management LLC’s holdings in Zoetis were worth $1,415,000 at the end of the most recent quarter.

Other large investors also recently bought and sold shares of the company. Prosperity Bancshares Inc purchased a new position in Zoetis during the fourth quarter worth about $25,000. Cassaday & Co Wealth Management LLC purchased a new stake in shares of Zoetis in the 1st quarter valued at approximately $28,000. Elyxium Wealth LLC acquired a new position in shares of Zoetis in the 4th quarter worth approximately $32,000. Root Financial Partners LLC lifted its holdings in shares of Zoetis by 66.5% in the 1st quarter. Root Financial Partners LLC now owns 258 shares of the company’s stock worth $30,000 after acquiring an additional 103 shares during the last quarter. Finally, Wellington Grp LLC boosted its position in shares of Zoetis by 6,675.0% during the 1st quarter. Wellington Grp LLC now owns 271 shares of the company’s stock worth $32,000 after purchasing an additional 267 shares during the period. Institutional investors and hedge funds own 92.80% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have issued reports on the company. HSBC cut their target price on Zoetis from $140.00 to $95.00 and set a “buy” rating on the stock in a research report on Monday, July 6th. Barclays dropped their price objective on Zoetis from $136.00 to $85.00 and set an “equal weight” rating for the company in a research note on Wednesday, July 1st. Wall Street Zen downgraded Zoetis from a “buy” rating to a “hold” rating in a report on Saturday, May 2nd. Morgan Stanley set a $85.00 target price on Zoetis in a report on Friday. Finally, Argus reaffirmed a “hold” rating on shares of Zoetis in a research report on Wednesday, May 27th. Seven investment analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Zoetis currently has an average rating of “Hold” and an average target price of $115.50.

Key Headlines Impacting Zoetis

Here are the key news stories impacting Zoetis this week:

• Positive Sentiment: Zoetis reported second-quarter adjusted earnings of $1.87 per share, above the $1.84–$1.85 analyst consensus and up from $1.76 a year earlier. The earnings beat provides some support for the stock. Zoetis Surpasses Q2 Earnings Estimates
• Positive Sentiment: JPMorgan lowered its price target from $130 to $115 but maintained an Overweight rating, implying substantial potential upside from recent levels. The target reduction reflects more conservative estimates rather than a bearish long-term view.
• Neutral Sentiment: Zoetis appointed James “Jay” Saccaro as executive vice president and chief financial officer, with the announcement also describing an expanded finance and operating leadership role. The change may improve execution, but its near-term effect on results is unclear. Zoetis Appoints Jay Saccaro
• Negative Sentiment: Second-quarter revenue was $2.47 billion, below the $2.50 billion consensus and essentially flat year over year. Management cited weaker veterinary traffic, customer price sensitivity and competitive pressure in companion-animal products, with promotions being used to defend market share. ZTS Q2 Earnings Call Flags Deeper Companion Animal Pressure
• Negative Sentiment: Zoetis cut fiscal 2026 guidance to adjusted EPS of $6.15–$6.25 from expectations near $6.87, and revenue guidance to $9.1–$9.3 billion versus consensus of roughly $9.8 billion. The outlook reduction is the primary reason the stock has declined despite the quarterly earnings beat. Zoetis Q2 Earnings Beat Estimates, Revenues Miss, 2026 View Cut

Insider Buying and Selling

In other news, Director Michael B. Mccallister bought 3,000 shares of the business’s stock in a transaction that occurred on Monday, May 11th. The shares were purchased at an average cost of $77.76 per share, for a total transaction of $233,280.00. Following the completion of the purchase, the director owned 24,524 shares of the company’s stock, valued at approximately $1,906,986.24. This represents a 13.94% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Frank A. Damelio bought 6,650 shares of Zoetis stock in a transaction that occurred on Wednesday, May 13th. The stock was purchased at an average cost of $75.39 per share, for a total transaction of $501,343.50. Following the acquisition, the director owned 21,458 shares of the company’s stock, valued at $1,617,718.62. This represents a 44.91% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Over the last ninety days, insiders have bought 11,650 shares of company stock worth $886,384. Company insiders own 0.22% of the company’s stock.

Zoetis Stock Down 6.1%

Shares of NYSE ZTS opened at $72.53 on Friday. The stock has a market cap of $30.41 billion, a P/E ratio of 11.95, a PEG ratio of 1.26 and a beta of 0.74. The business’s fifty day simple moving average is $76.66 and its 200-day simple moving average is $100.75. Zoetis Inc. has a 12-month low of $71.47 and a 12-month high of $160.48. The company has a current ratio of 3.15, a quick ratio of 1.91 and a debt-to-equity ratio of 2.80.

Zoetis (NYSE:ZTS) last released its earnings results on Thursday, August 6th. The company reported $1.87 EPS for the quarter, topping the consensus estimate of $1.85 by $0.02. Zoetis had a return on equity of 70.95% and a net margin of 27.49%.The firm had revenue of $2.47 billion during the quarter, compared to analysts’ expectations of $2.50 billion. During the same period in the previous year, the firm posted $1.76 EPS. Zoetis’s revenue for the quarter was down .2% on a year-over-year basis. Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. As a group, equities analysts predict that Zoetis Inc. will post 6.43 EPS for the current fiscal year.

Zoetis Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 1st. Stockholders of record on Monday, July 20th will be given a dividend of $0.53 per share. The ex-dividend date of this dividend is Monday, July 20th. This represents a $2.12 dividend on an annualized basis and a dividend yield of 2.9%. Zoetis’s payout ratio is currently 34.93%.

About Zoetis

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.